BCG040 / Biocytogen - LARVOL DELTA

BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

ADC • Heterogeneity • Preclinical • Oncology • VTCN1

BCG040, a novel B7-H4-targeting biparatopic ADC, demonstrates superior preclinical efficacy in heterogeneous tumors (AACR 2026) - "In vivo, a single low dose of BCG040 showed durable tumor regressions (~40 days) in breast cancer PDX models and significant efficacy in pancreatic cancer PDX models, outperforming other ADCs such as Hu2F7, SGN-B7H4V, or FPA150 (conjugated with MMAE or BCPT02). Notably, BCPT02-containing ADCs exhibited potent antitumor activity in heterogeneous PDX tumors, whereas MMAE-based conjugates were ineffective. These findings underscore the potential of BCG040 as a promising therapeutic candidate for the treatment of pancreatic, biliary tract, ovarian, and breast cancers."

ADC • Heterogeneity • Preclinical • Breast Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • TOP1 • VTCN1